Santosh Kumar Adla
Overview
Explore the profile of Santosh Kumar Adla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
74
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kralova A, Montaser A, Tampio J, Adla S, Jalkanen A, Rysa J, et al.
Eur J Pharmacol
. 2025 Feb;
995:177409.
PMID: 39986592
Neuroinflammation has been implicated as a pathological contributor to several neurodegenerative disorders. Increasing evidence suggests that paracetamol (PCM, acetaminophen) has unappreciated anti-neuroinflammatory properties. However, PCM possesses hepatotoxicity in higher dosages,...
2.
Rahnasto-Rilla M, Puumalainen T, Karttunen V, Adla S, Lahtela-Kakkonen M
Bioorg Med Chem
. 2024 Sep;
112:117884.
PMID: 39226716
Small molecule inhibitors targeting the bromodomain and extra-terminal domain (BET) family proteins have emerged as a promising class of anti-cancer drugs. Nevertheless, the clinical advancement of these agents has been...
3.
Adla S, Virtanen H, Thongsodsaeng T, Huttunen K
Neurochem Int
. 2024 May;
177:105771.
PMID: 38761853
For most diseases and disorders occurring in the brain, the full causes behind them are yet unknown, but many show signs of dysfunction of amino acid transporters or abnormalities in...
4.
Munawar Cheema M, Macakova Kotrbova Z, Hrcka Krausova B, Adla S, Slavikova B, Chodounska H, et al.
J Steroid Biochem Mol Biol
. 2024 Jan;
239:106464.
PMID: 38246201
Endogenous neurosteroids (NS) and their synthetic analogs, neuroactive steroids (NAS), are potentially useful drug-like compounds affecting the pathophysiology of miscellaneous central nervous system disorders (e.g. Alzheimer´s disease, epilepsy, depression, etc.)....
5.
Jarvinen J, Montaser A, Adla S, Leppanen J, Lehtonen M, Vellonen K, et al.
Eur J Pharm Sci
. 2023 Nov;
192:106637.
PMID: 37967656
Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, is currently used clinically for treating hormone receptor-positive and human epidermal growth factor receptor 2 negative breast cancer. Additionally, it has the potential...
6.
Tonduru A, Maljaei S, Adla S, Anamea L, Tampio J, Kralova A, et al.
J Med Chem
. 2023 Nov;
66(22):15094-15114.
PMID: 37930268
OATP1C1 (organic anion-transporting polypeptide 1C1) transports thyroid hormones, particularly thyroxine (T), into human astrocytes. In this study, we investigated the potential of utilizing OATP1C1 to improve the delivery of anti-inflammatory...
7.
Tonduru A, Adla S, Huttunen K, Kronenberger T, Poso A
Molecules
. 2022 Dec;
27(23).
PMID: 36500622
To better understand the functionality of organic anion transporting polypeptides (OATPs) and to design new ligands, reliable structural data of each OATP is needed. In this work, we used a...
8.
Markowicz-Piasecka M, Darlak P, Markiewicz A, Sikora J, Adla S, Bagina S, et al.
Eur J Pharm Biopharm
. 2022 Nov;
181:249-262.
PMID: 36372271
Although many pharmaceuticals have therapeutic potentials for central nervous system (CNS) diseases, few of these agents have been effectively administered. It is due to the fact that the blood-brain barrier...
9.
Huttunen J, Adla S, Markowicz-Piasecka M, Huttunen K
Pharmaceutics
. 2022 Jun;
14(6).
PMID: 35745806
Membrane transporters have a crucial role in compounds' brain drug delivery. They allow not only the penetration of a wide variety of different compounds to cross the endothelial cells of...
10.
Markowicz-Piasecka M, Markiewicz A, Darlak P, Sikora J, Adla S, Bagina S, et al.
Neurotherapeutics
. 2022 Apr;
19(3):942-976.
PMID: 35391662
One of the greatest challenges with successful pharmaceutical treatments of central nervous system (CNS) diseases is the delivery of drugs into their target sites with appropriate concentrations. For example, the...